Compare CARG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARG | NAMS |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2017 | 2022 |
| Metric | CARG | NAMS |
|---|---|---|
| Price | $28.89 | $21.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $41.27 | ★ $49.73 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | 32.81 |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $316,861,000.00 | $22,503,000.00 |
| Revenue This Year | $11.86 | $30.15 |
| Revenue Next Year | $9.04 | $384.12 |
| P/E Ratio | $33.61 | ★ N/A |
| Revenue Growth | ★ 59.92 | N/A |
| 52 Week Low | $26.39 | $20.91 |
| 52 Week High | $41.22 | $42.21 |
| Indicator | CARG | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 34.29 |
| Support Level | $26.81 | $21.02 |
| Resistance Level | $36.03 | $25.59 |
| Average True Range (ATR) | 1.26 | 1.14 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 16.58 | 9.82 |
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. It provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listings, through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments, namely U.S. Marketplace and Digital Wholesale. It generates maximum revenue from the U.S. Marketplace segment. Geographically, the company derives its key revenue from the United States and the rest from international markets.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.